TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded TriSalus Life Sciences from “hold” to “sell.” Despite mixed analyst views—including three Buy ratings—the consensus rating remains Hold, with an average price target of $10.20.
• TriSalus shares were reported down 7.9%, opening at $3.25, below their 50-day and 200-day moving averages.
• The company reported a quarterly loss of $0.16 per share, matching estimates, while revenue of $11.41 million exceeded the $10.27 million consensus estimate.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on the stock. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a research note on Wednesday. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday, September 23rd. HC Wainwright raised their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Wednesday, September 23rd. Finally, Zacks Research upgraded shares of TriSalus Life Sciences to a "hold" rating in a research report on Thursday, September 10th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $10.20.

TriSalus Life Sciences Trading Down 7.9%

TLSI opened at $3.25 on Friday. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The company has a 50-day simple moving average of $4.28 and a 200 day simple moving average of $4.36. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. On average, research analysts predict that TriSalus Life Sciences will post -0.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TLSI. Russell Investments Group Ltd. acquired a new position in TriSalus Life Sciences in the third quarter valued at about $68,000. Provenance Wealth Advisors LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $94,000. CWA Asset Management Group LLC bought a new position in TriSalus Life Sciences in the 3rd quarter valued at about $310,000. State Street Corp increased its stake in shares of TriSalus Life Sciences by 86.3% in the second quarter. State Street Corp now owns 610,963 shares of the company's stock valued at $2,780,000 after buying an additional 282,943 shares during the period. Finally, First Light Asset Management LLC boosted its stake in TriSalus Life Sciences by 29.3% in the second quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company's stock valued at $29,814,000 after acquiring an additional 1,485,664 shares during the last quarter. Institutional investors own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.